Epigral Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹736Cr
- +17.2% YoY
- +23.3% QoQ
- Net profit
- ₹82Cr
- −5.7% YoY
- +110.3% QoQ
- Margin
- 23%
- −5 pp YoY
- +6 pp QoQ
Guidance rank: #31 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
The company targets a volume growth of around 10% to 12% for FY27. Epigral targets a volume growth of around 10% to 12% for FY27, driven by capacity expansions in higher value products like CPVC and ECH.
From Epigral Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a volume growth of around 10% to 12% for FY27.
- Revenue growth is expected to improve over FY26, with FY27 anticipated to be better than FY26 in terms of volume and value growth.
- Capacity additions, especially commissioning of CPVC and Epichlorohydrin (ECH) units, are on track and expected to support growth.
- Gradual ramp-up to optimum utilization levels by FY28 is planned (CPVC approximately 75%, ECH around 80%).
- Chlorotoluene product line is expected to contribute sizably in FY27, with volume ramp-up continuing.
2 more points from Epigral Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Epigral Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Epigral is commissioning capacity expansion projects for Epichlorohydrin (ECH) and CPVC in Q2 FY27, expected to ramp up gradually and reach optimum utilization (CPVC ~75%, ECH ~80%) by FY28.
- They are working on a new greenfield project; site evaluation and due diligence are ongoing with plans to announce the project within the current year to sustain post-FY29 growth.
- No immediate plans to expand caustic soda capacity, but future capacity increase possible if required.
- The company follows a cautious, step-by-step capex approach, announcing new projects as existing ones near completion.
2 more points from Epigral Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Epigral Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Epigral Ltd's call on order book
Create a free account to keep reading this call
Epigral Ltd — Quarterly revenue & net profit
Epigral Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 736 | 628 | +17.2% | 597 | +23.3% |
| Operating profit (EBITDA) | 169 | 173 | -2.3% | 103 | +64.1% |
| Operating margin | 23% | 28% | -5 pp | 17% | +6 pp |
| Profit before tax | 111 | 131 | -15.3% | 55 | +101.8% |
| Net profit (PAT) | 82 | 87 | -5.7% | 39 | +110.3% |
| EPS (₹) | 18.99 | 20.08 | -5.4% | 9.07 | +109.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹64 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Epigral's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Indian Phosphate (Q4 FY26)
H2 FY26 Revenue (Consolidated):** ₹580.25 Cr, up from ₹451.59 Cr in H2 FY25 — a year-on-year increase of ₹128.66 Cr. Key investor presentation takeaways from In
- Paragon Fine (Q4 FY26)
Revenue for H2FY26:** Rs 68.88 Cr, up 7.41% YoY from Rs 64.13 Cr in H2FY25 (Page 22). Key investor presentation takeaways from Paragon Fine's Q4 FY26 investor p
- IVP (Q4 FY26)
Q4 FY26 revenue from operations: ₹164.44 crore . Key investor presentation takeaways from IVP's Q4 FY26 investor presentation — and how it ranks against sector
- Vishnu Chemicals (Q4 FY26)
Q4 FY26 Operating Revenues: ₹450.3 crore, up 14.7% YoY from ₹392.6 crore in Q4 FY25 (Page 5). Key investor presentation takeaways from Vishnu Chemicals Ltd's Q4
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Epigral Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Epigral Ltd Q4 FY26 results?
The company targets a volume growth of around 10% to 12% for FY27. Epigral targets a volume growth of around 10% to 12% for FY27, driven by capacity expansions in higher value products like CPVC and ECH.
What is Epigral Ltd share price analysis?
Epigral Ltd currently shows a neutral. The stock trades at a P/E of 17.8 with a market cap of ₹4,828 Cr. Investors should review the full earnings analysis for detailed insights.
Is Epigral Ltd planning capital expenditure?
Epigral is commissioning capacity expansion projects for Epichlorohydrin (ECH) and CPVC in Q2 FY27, expected to ramp up gradually and reach optimum utilization (CPVC ~75%, ECH ~80%) by FY28.
Keep Epigral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
